Behavioral ImprovementsEncouraging behavioral changes were observed in the first two patients, implying improvements in hearing capabilities.
Competitive AdvantageAudiogene focuses exclusively on recruiting cochlear implant-naïve patients 6-31 months old, allowing assessment of the direct impact of ‘501 on both hearing restoration and language acquisition and development – a potential competitive advantage.
Gene Therapy ImpactThe Audiogene study is enrolling younger patients naïve of cochlear implants, positioning ALSEN to demonstrate the potential impact of gene therapy on speech acquisition and development.